

## Beyond Inhibition. Reprogramming Cancer Control.

Kazia Therapeutics Limited (“Kazia”) is a Sydney-based clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet need.

### Financial Insights

#### Cash & Cash Equivalents:

~ US\$46 million

(Runway expected to fund planned operations into 2029, excluding additional or expanded trials)

#### Debt:

No outstanding debt

**Ticker:** KZIA (NASDAQ)

#### American Depositary Shares

#### Outstanding:

~ 11.4 million




### Key Investment Highlights

- Portfolio/Pipeline:** The portfolio includes two clinical-stage small-molecule programs: (1) paxalisib, a brain-penetrant dual inhibitor of the PI3K/AKT/mTOR pathway, a critical signaling route that helps cancer cells grow and multiply, licensed from Genentech, and (2) EVT801, a selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor discovered by Sanofi and licensed from Evotec SE. Additionally, Kazia has an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 protein degrader platform (lead compound NDL2), alongside worldwide rights to combination IP that covers pairing PI3K inhibitors with other cancer therapies including immunotherapies and PARP inhibitors.
- Partnerships and Collaborations:** Simcere (Greater China), Sovargen (select neurology), QIMR Berghofer (first-in-class PD-L1 degrader platform, research collaborations), Pacific Pediatric Neuro-Oncology Consortium, Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, and Dana-Farber Cancer Institute.
- Proven Leadership:** Dr. John Friend, CEO, and Jeffrey Kraws, Head of Corporate Strategy & Development, bring clinical, operational, and market expertise to support current and future phases of development.
- Intellectual Property:** Kazia and its partners maintain a global intellectual property portfolio supporting development and durable competitive positioning.

# Milestones & Anticipated Catalysts

- Q4 2025** Pricing of \$50 million private placement of equity securities
- Q1 2026** Clinical trial update; Complete metabolic response in stage IV TNBC expanded access patient and 2 partial responses in metastatic TNBC Phase 1b study
- Q1 2026** PD-L1 protein degrader platform update
- Q2 2026** Update from FDA discussion regarding paxalisib commercial and development path forward in GBM
- Q2 2026** Advancement of NDL2 PD-L1 degrader program toward IND-enabling studies
- 2H 2026** Readouts from neuro-oncology focused clinical trials in patients with GBM and brain metastases
- 2H 2026** Clinical efficacy and biomarker data from ongoing Phase 1b breast cancer study
- 2H 2026** Provide update of paxalisib pre-clinical development into additional breast cancer subtypes
- 2H 2026** Publication/Presentation of translational data supporting therapeutic reprogramming strategy for paxalisib

## Pipeline Snapshot



IDH: Isocitrate dehydrogenase, DIPG: Diffuse Intrinsic Pontine Glioma, AT / RT : Atypical Teratoid Rhabdoid Tumor, CNS: central nervous system, VEGFR3: vascular endothelial growth factor receptor 3  
 \*Product candidates (not approved)